Investor Presentation

89 Investor presentation First six months of 2022 Innovative late-stage CVD pipeline provides opportunities to make a difference for many patients Focus areas Near-term Leverage broader CV indications to establish presence with Cardiologists and build an adequate PCP footprint for entry of stand-alone CVD product Medium-term Utilise leading scientific and commercial capabilities to launch first CVD stand-alone product Long-term Examples of unmet needs in CVD pipeline Category Broader indications Stand-alone CVD Novo NordiskⓇ Study Current phase HFPEF Phase 3 Sema 2.4mg PAD Phase 3 Sema 1.0mg ATTR-CM Phase 2 to be initiated in 2022 NNC6019 Global unmet need (people) ~13m ~200m No consensus (estimated 0.1- 2.8 cases per 10,000 in EU) Potential differentiators 1st in class indication1 First and only for T2D Reverse disease pathology Expand pipeline with differentiated MoAs through leading discovery and translational capabilities Potential launch year 2023/24 2023/24 2028 1 Specifically for a functional outcomes trial in an obese patient population PCP: Primary Care Physician; CV(D): Cardiovascular Disease; MOA: Mode of Action; HFPEF: Heart failure with preserved ejection fraction; PAD: Peripheral arterial disease; ATTR-CM: Transthyretin Amyloid Cardiomyopathy; T2D: Type 2 Diabetes Sources: HFPEF: Savarese G, Lund LH. Global Public Health Burden of Heart Failure, 3 April 2017; PAD: Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and evidence-based facts, 22 May 2018; ATTR-CM: Orphan Maintenance Assessment Report for tafamidis, EMA, 17 February 2020

View entire presentation